Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma

Mené sur 90 patients atteints d'un lymphome folliculaire récidivant ou réfractaire (durée médiane de suivi : 18,3 mois), cet essai international de phase II évalue l'efficacité, du point de vue du taux de réponse complète, et la sécurité du mosunétuzumab, un anticorps monoclonal bi-spécifique anti-CD3/CD20

Résumé en anglais

Follicular lymphoma has a chronic clinical course with an overall survival of 80% at 10 years, justifying its classification as an indolent B-cell lymphoma. Unfortunately, follicular lymphoma is a heterogenous disease, and about one in five patients relapses within 2 years after the start of initial treatment. Furthermore, retrospective data have shown that progression-free survival and overall survival substantially decrease in the relapsed setting, reflecting the clinical experience that patients with follicular lymphoma become more treatment-resistant in later lines of therapy. Thus, despite the generally indolent nature of follicular lymphoma, a great unmet medical need exists for efficient treatments for patients with relapsed or refractory follicular lymphoma, and the therapeutic armamentarium for later lines of treatment is particularly scarce. To read this article in full you will need to make a payment.